CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-01 | LEONARD JOHN M President and CEO | Grant or award | +136,000 | 1,077,115 | ||
| 2025-03-01 | LEONARD JOHN M President and CEO | Grant or award · Stock Option (right to buy) | +196,000 | 196,000 | ||
| 2025-03-01 | Dulac Edward J III EVP, Chief Financial Officer | Grant or award | +47,200 | 113,524 | ||
| 2025-03-01 | Dulac Edward J III EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +67,429 | 67,429 | ||
| 2025-03-01 | Dube Michael P VP, Chief Accounting Officer | Grant or award | +14,000 | 59,640 | ||
| 2025-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award | +43,200 | 130,866 | ||
| 2025-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +61,714 | 61,714 | ||
| 2025-03-01 | Schultes Birgit C EVP, Chief Scientific Officer | Grant or award | +37,600 | 105,215 | ||
| 2025-03-01 | Schultes Birgit C EVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +53,714 | 53,714 | ||
| 2025-03-01 | BASTA JAMES EVP, General Counsel | Grant or award | +40,000 | 114,497 | ||
| 2025-03-01 | BASTA JAMES EVP, General Counsel | Grant or award · Stock Option (right to buy) | +57,143 | 57,143 | ||
| 2025-01-29 | Bhanji Muna Director | Sale 10b5-1 | −265 | $9.97 | $3K | 19,468 |
| 2025-01-03 | Dube Michael P VP, Chief Accounting Officer | Sale | −1,372 | $12.18 | $17K | 45,640 |
| 2025-01-03 | BASTA JAMES EVP, General Counsel | Sale | −7,074 | $12.18 | $86K | 74,497 |
| 2025-01-03 | Lebwohl David EVP, Chief Medical Officer | Sale | −9,557 | $12.18 | $116K | 87,666 |
| 2025-01-03 | Hicks Derek EVP, Chief Business Officer | Sale | −6,502 | $12.18 | $79K | 59,878 |
| 2025-01-03 | LEONARD JOHN M President and CEO | Sale | −26,807 | $12.18 | $327K | 941,115 |
| 2025-01-03 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −8,966 | $12.18 | $109K | 77,388 |
| 2025-01-03 | Clark Eliana EVP, Chief Technical Officer | Sale | −7,422 | $12.18 | $90K | 64,048 |
| 2025-01-02 | Clark Eliana EVP, Chief Technical Officer | Sale | −556 | $12.03 | $7K | 71,470 |
Page 5 of 40 · 783 trades